Cahill Represents Initial Purchasers in $450 Million Notes Offering for Emergent BioSolutions Inc.
Date: 08/07/20
Cahill represented the initial purchasers in connection with a Rule 144A offering of $450,000,000 in aggregate principal amount of 3.875% senior notes due 2028 by Emergent BioSolutions Inc. Proceeds from the offering were used to refinance existing indebtedness and for general corporate purposes. Emergent BioSolutions Inc. is a global life sciences company focused on providing to civilian and military populations a portfolio of innovative preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats.